<div id="readability-page-1"><p><span>Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report)</span> was downgraded by equities researchers at Wall Street Zen from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report issued on Saturday.</p><ul><li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li></ul><p>Several other equities research analysts have also weighed in on the company. Hsbc Global Res upgraded Regeneron Pharmaceuticals to a &#34;strong-buy&#34; rating in a research report on Monday, November 24th. Guggenheim raised their price objective on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a &#34;buy&#34; rating in a research report on Wednesday, October 29th. HSBC began coverage on shares of Regeneron Pharmaceuticals in a report on Monday, November 24th. They set a &#34;buy&#34; rating and a $255.00 target price on the stock. BMO Capital Markets increased their price target on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the stock an &#34;outperform&#34; rating in a research note on Thursday, December 4th. Finally, Royal Bank Of Canada boosted their price objective on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a &#34;sector perform&#34; rating in a research note on Wednesday, October 29th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, eight have assigned  a Hold rating and one  has given a Sell rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals  has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $779.45.</p><p><b>Read Our Latest Stock Report on REGN</b></p><h2>Regeneron Pharmaceuticals Price Performance</h2><ul><li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li></ul><p>Shares of NASDAQ REGN opened at $767.96 on Friday. Regeneron Pharmaceuticals has a 1 year low of $476.49 and a 1 year high of $790.98. The stock has a market capitalization of $80.71 billion, a P/E ratio of 18.39, a P/E/G ratio of 2.15 and a beta of 0.37. The company's 50-day moving average is $682.40 and its 200 day moving average is $599.63. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.33. </p><p>Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The business had revenue of $3.75 billion during the quarter, compared to analyst estimates of $3.57 billion. During the same period last year, the business posted $12.46 earnings per share. Regeneron Pharmaceuticals's quarterly revenue was up .9% compared to the same quarter last year.  On average, sell-side analysts expect that  Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year. </p><h2>Insiders Place Their Bets</h2><ul><li>Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025</li></ul><p>In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 431 shares of the company's stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the sale, the vice president owned 4,233 shares in the company, valued at $2,757,503.19. This represents a 9.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Christine A. Poon sold 6,500 shares of the firm's stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the sale, the director owned 2,352 shares in the company, valued at approximately $1,538,843.04. The trade was a 73.43% decrease in their position. The disclosure for this sale is available in the SEC filing. 7.02% of the stock is currently owned by corporate insiders. </p><h2>Institutional Inflows and Outflows</h2><p>Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Keel Point LLC bought a new stake in shares of  Regeneron Pharmaceuticals during the third quarter valued at approximately $251,000.  CTC Alternative Strategies Ltd. bought a new stake in  Regeneron Pharmaceuticals in the 3rd quarter valued at $307,000.  Allworth Financial LP lifted its stake in  Regeneron Pharmaceuticals by 50.5% in the 3rd quarter. Allworth Financial LP now owns 1,496 shares of the biopharmaceutical company's stock worth $841,000 after purchasing an additional 502 shares in the last quarter.  IFP Advisors Inc boosted its holdings in shares of  Regeneron Pharmaceuticals by 14.2% during the 3rd quarter. IFP Advisors Inc now owns 1,405 shares of the biopharmaceutical company's stock valued at $790,000 after purchasing an additional 175 shares during the last quarter.  Finally, Swiss Life Asset Management Ltd grew its position in shares of  Regeneron Pharmaceuticals by 112.0% during the third quarter. Swiss Life Asset Management Ltd now owns 23,658 shares of the biopharmaceutical company's stock valued at $13,302,000 after purchasing an additional 12,500 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors. </p><h2>About Regeneron Pharmaceuticals</h2> (Get Free Report)<p>Regeneron Pharmaceuticals, Inc <span>NASDAQ: REGN<span></span></span> is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.  </p><p>Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Regeneron Pharmaceuticals</li><li>Stock Sentiment Analysis: How it Works</li><li>Nike Beats on Earnings But Struggles in China and Faces Tariffs</li><li>How to Read Stock Charts for Beginners</li><li>Is the AI Boom a Bubble? These 2 Dividend Stocks Say No</li><li>Insider Trading - What You Need to Know</li><li>4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and More</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Regeneron Pharmaceuticals Right Now?</h2><p>Before you consider Regeneron Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.</p><p>While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

REGN

<p>Wall Street Zen downgraded Regeneron Pharmaceuticals from a "buy" to a "hold" rating. Other analysts have varied opinions, with some upgrading to "strong-buy" and others adjusting price targets. The stock has a consensus "Moderate Buy" rating with a target price of $779.45. Recent insider trading and institutional investments are also noted.</p>

Regeneron Pharmaceuticals (NASDAQ:REGN) Downgraded to Hold Rating by Wall Street Zen